Drug Sales Trends for CARDIZEM CD

Annual Sales Revenues and Units Sold for CARDIZEM CD

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
CARDIZEM CD			2021
CARDIZEM CD			2020
CARDIZEM CD			2019
CARDIZEM CD			2018
CARDIZEM CD			2017
CARDIZEM CD			2016
CARDIZEM CD			2015

Market Analysis and Sales Projections for CARDIZEM CD

Introduction

CARDIZEM CD, a formulation of diltiazem hydrochloride, is a widely prescribed medication for the treatment of hypertension and angina. Here, we will delve into the market analysis and sales projections for this drug, considering various factors such as market dynamics, competition, and regulatory environments.

Market Size and Growth

The North America diltiazem market, which includes CARDIZEM CD, is projected to experience significant growth. From 2021 to 2028, the market is expected to grow from $161.53 million to $369.22 million, with a Compound Annual Growth Rate (CAGR) of 12.5%[3].

Market Segments

The diltiazem market in North America is segmented into several product types and applications.

Product Types

• Capsules: CARDIZEM CD is available in extended-release capsule form and is expected to witness the fastest CAGR from 2021 to 2028. This segment is growing due to the convenience and efficacy of once-daily dosing[3].
• Tablets: Although tablets held the largest share of the market in 2021, the capsules segment is gaining traction.
• Injection: This segment, though smaller, is also part of the overall market.

Applications

• Hypertension: This segment held the largest share of the market in 2021. CARDIZEM CD is highly effective in lowering diastolic blood pressure in a linear manner across various doses[1][4].
• Angina: The angina segment is expected to grow at the fastest CAGR during the coming years, driven by the increasing incidence of cardiovascular diseases[3].

Market Drivers

Several factors are driving the growth of the diltiazem market, including:

Increase in Cardiovascular Disease Incidence

The rise in cardiovascular diseases is a significant driver, as more patients are being diagnosed and treated with medications like CARDIZEM CD[3].

Increasing Elderly Population

The elderly population, which is more prone to heart diseases, is increasing, leading to higher demand for diltiazem-based medications[3].

Market Restraints

Despite the growth drivers, there are also some restraints to consider:

Side Effects of Diltiazem

The side effects associated with diltiazem consumption, such as potential interactions with alcohol and other medications, could negatively impact market growth[3].

Competitive Landscape

The competitive landscape for CARDIZEM CD has been influenced by antitrust issues and the entry of generic competitors.

Antitrust Litigation

Hoechst Marion Roussel (HMR), the original manufacturer of CARDIZEM CD, was involved in an antitrust lawsuit for attempting to delay the entry of generic competitors. This led to a consent agreement that barred such practices in the future[5].

Generic Competition

The entry of generic versions of diltiazem has significantly impacted the market. Pharmacies and wholesalers are expected to stock generic versions as soon as they are available, driven by consumer demand and third-party insurance requirements[2].

Sales Projections

Given the market dynamics, here are some key points regarding sales projections:

Historical Sales

CARDIZEM CD was once HMR's largest-selling product, generating around $750 million annually before the entry of generic competitors[5].

Future Projections

Despite the competition from generics, the overall diltiazem market is expected to grow. The capsules segment, in particular, is projected to see significant growth due to its convenience and efficacy. However, the market share of CARDIZEM CD specifically may decline as generic alternatives capture a larger share of the market[3].

Impact of COVID-19

The COVID-19 pandemic has had a positive impact on the pharmaceutical industry, including the diltiazem market. The increased focus on healthcare and the development of vaccines and drugs have boosted the market growth[3].

Pharmacokinetics and Clinical Impact

CARDIZEM CD's pharmacokinetics and clinical effects are crucial for its market performance. The drug decreases vascular resistance, increases cardiac output, and lowers diastolic blood pressure without causing reflex tachycardia. These therapeutic effects contribute to its popularity among patients and healthcare providers[1][4].

Key Takeaways

• The North America diltiazem market, including CARDIZEM CD, is expected to grow significantly from 2021 to 2028.
• The capsules segment is projected to witness the fastest growth.
• Hypertension remains the largest application segment.
• Antitrust issues and generic competition have impacted the market.
• The COVID-19 pandemic has positively affected the pharmaceutical industry.

Frequently Asked Questions (FAQs)

Q: What is the primary use of CARDIZEM CD? A: CARDIZEM CD is primarily used for the treatment of hypertension and angina.

Q: How does CARDIZEM CD affect blood pressure? A: CARDIZEM CD lowers diastolic blood pressure in a linear manner across various doses and decreases vascular resistance without causing reflex tachycardia[1][4].

Q: What is the impact of generic competition on CARDIZEM CD sales? A: Generic competition has significantly impacted CARDIZEM CD sales, as pharmacies and wholesalers are expected to stock generic versions as soon as they are available[2].

Q: How has the COVID-19 pandemic affected the diltiazem market? A: The COVID-19 pandemic has had a positive impact on the diltiazem market, boosting growth due to increased focus on healthcare and pharmaceutical development[3].

Q: What are the potential side effects of diltiazem that could impact market growth? A: Potential side effects include interactions with alcohol and other medications, which could negatively impact market growth[3].

Cited Sources:

1. DailyMed - CARDIZEM CD- diltiazem hydrochloride capsule, coated, extended release
2. Casetext - In re Cardizem CD Antitrust Litigation
3. Business Market Insights - North America Diltiazem Market report 2028
4. FDA - 020062Orig1s042.pdf
5. FTC - Consent Agreement Resolves Complaint Against Pharmaceutical Companies